anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1. Open the wallet containing blister card. There are 21 light orange "active" pills and 7 green "reminder" pills.
  2. The wallet comes to you set up for Sunday Start. If you are to start pill-taking on Sunday, take your first light orange pill on the first Sunday after your menstrual period begins. If your period begins on Sunday, take your first pill that day. Push down on the first light orange "active" pill of wallet (Sunday) with your thumb or forefinger. The pill will come out through a hole in the back of the package.
  3. If you are to start pill-taking on "Day 1", the enclosed calendar label has been provided and will be placed over the calendar printed on the wallet. To put label in place, identify your correct starting day of the week, locate that day label present in the calendar label and affix that day label over the printed calender on the wallet. Push down on the light orange "active" pill of wallet with your thumb or forefinger. The pill will come out through a hole in the back of the package.
  4. The first light orange "active" pill you will take is indicated by START and lines up with the black Day Arrow as indicated on the wallet. For details, see the directions in the following picture. Continue taking one pill daily, until no pill remains by last day of the third week.



5\. The next day take the green "reminder" pill from the wallet that corresponds with the day of the week it happens to be. Take a green pill each day until all seven pills are taken. During this time your period should begin.

6\. After you have taken all the green pills, begin a new wallet containing blister card (see Step 1 above in "Instructions for Use") and take the first light orange "active" pill on the next day, even if your period is not yet over. 

STORAGE: Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). [see USP Controlled Room Temperature].

DETAILED PATIENT LABELING

This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted diseases.

PLEASE NOTE: This labeling is revised from time to time as important new medical information becomes available. Therefore, please review this labeling carefully.

The following oral contraceptive product contains a combination of a progestogen and estrogen, the two kinds of female hormones:

Enskyce™ (desogestrel and ethinyl estradiol) Tablets

Each light orange tablet contains 0.15 mg desogestrel and 0.03 mg ethinyl estradiol. Each green tablet contains inert ingredients.
PURPOSE: To employ bioinformatics and machine learning to predict the characteristics of immune cells and genes associated with the inflammatory response and ferroptosis in chronic obstructive pulmonary disease (COPD) patients and to aid in the development of targeted traditional Chinese medicine (TCM). Mendelian randomization analysis elucidates the causal relationships among immune cells, genes, and COPD, offering novel insights for the early diagnosis, prevention, and treatment of COPD. This approach also provides a fresh perspective on the use of traditional Chinese medicine for treating COPD.
METHODS: R software was used to extract COPD-related data from the Gene Expression Omnibus (GEO) database, differentially expressed genes were identified for enrichment analysis, and WGCNA was used to pinpoint genes within relevant modules associated with COPD. This analysis included determining genes linked to the inflammatory response in COPD patients and analyzing their correlation with ferroptosis. Further steps involved filtering core genes, constructing TF-miRNA‒mRNA network diagrams, and employing three types of machine learning to predict the core miRNAs, key immune cells, and characteristic genes of COPD patients. This process also delves into their correlations, single-gene GSEA, and diagnostic model predictions. Reverse inference complemented by molecular docking was used to predict compounds and traditional Chinese medicines for treating COPD; Mendelian randomization was applied to explore the causal relationships among immune cells, genes, and COPD.
RESULTS: We identified 2443 differential genes associated with COPD through the GEO database, along with 8435 genes relevant to WGCNA and 1226 inflammation-related genes. A total of 141 genes related to the inflammatory response in COPD patients were identified, and 37 core genes related to ferroptosis were selected for further enrichment analysis and analysis. The core miRNAs predicted for COPD include hsa-miR-543, hsa-miR-181c, and hsa-miR-200a, among others. The key immune cells identified were plasma cells, activated memory CD4 T cells, gamma delta T cells, activated NK cells, M2 macrophages, and eosinophils. Characteristic genes included EGF, PLG, PTPN22, and NR4A1. A total of 78 compounds and 437 traditional Chinese medicines were predicted. Mendelian randomization analysis revealed a causal relationship between 36 types of immune cells and COPD, whereas no causal relationship was found between the core genes and COPD.
CONCLUSION: A definitive causal relationship exists between immune cells and COPD, while the prediction of core miRNAs, key immune cells, characteristic genes, and targeted traditional Chinese medicines offers novel insights for the early diagnosis, prevention, and treatment of COPD.
Purpose: To compare the effects of 12-week high-intensity interval (HIIT), moderate-intensity continuous (MICT), and self-selected intensity training (SSIT) on health outcomes and affective responses. Methods: Seventy-three overweight/obese inactive adults (62% woman; age, 31.4 ± 7.2 years; height, 1.66 ± 0.09 cm; Body mass index, 28.9 ± 2.7 kg.m-2) who were randomized into HIIT (n = 23), MICT (n = 24) and SSIT (n = 26) groups. The training was conducted three times per week in an outdoor environment, with 4 weeks under direct supervision and 8 weeks with semi-supervision. Cardiorespiratory fitness, body composition, and metabolic profile were evaluated at baseline and at the end of the 4th and 12th weeks. Core affect was measured during all training sessions. Results: Peak oxygen uptake improved in all groups after 4 and 12 weeks compared with baseline. Only the SSIT had reductions in body fat throughout the intervention. No improvements were observed in the metabolic profile across all groups. SSIT was perceived as more pleasurable than HIIT; however, there were no differences in affective responses between SSIT and MICT. Affective responses in-task (e.g. negative and positive peak, rate of change and affect at the end of the exercise session) predicted the HIIT and SSIT exercises attendance rate. Conclusion: Regardless of the exercise training protocol, overweight/obese inactive adults improved health outcomes, which suggests the prescribing HIIT, MICT, and SSIT in outdoor environments. SSIT should be considered in order to optimize the pleasure during training sessions. Affective response more positive in-task of the HIIT and SSIT is associated with greater attendance rate in these exercise protocols.
This is a single center, randomized, double-blind, 2-period, crossover study. A total of 24 subjects will be enrolled in the study; subjects will be dosed as 2 groups of 12 subjects each. Additional subjects may be enrolled into the study to obtain the statistical power of 90%. Subjects will attend a screening visit within 28 days prior to Period 1, and eligible subjects will then return to the clinic on the evening prior to Day -1. On Day 1, prior to dosing, subjects will be randomized to receive either CE-Iohexol Injection or the reference product during the first treatment period and the alternate product during the second treatment period. In each period, the study drug will be administered after a fasting period ≥8 hours. Each dose of intravenous iohexol will be separated by a minimum of a 7-day washout period. The test or reference product (iohexol 350 mg Iodine/mL, 80 mL) will be infused at a high flow rate of 4 mL/second for a dose of 400 mgI/kg for 70 kg subject. The test or reference product will be administered using a power injector. Plasma samples for determination of iohexol concentrations will be obtained from arm #2 (the arm not used for dosing) at 0 (pre-dose), 30 seconds, 5, 10, 15, 20, 30 and 45 minutes, and 1, 2, 3, 4, 6, 8, 12, 24, and 48 hours after infusion start; the 30-second sample obtained at the end of infusion. Subjects will be discharged from the clinic on Day 3 following collection of the 48-hour blood sample.
The invention discloses an extraction method of an immature bitter orange extract. Wherein the extract comprises pectin, synephrine, hesperidin, fructus Aurantii Immaturus total flavone and plant fiber. Selecting fructus Aurantii Immaturus material with diameter of 1.5cm or less. Extracting with hydrochloric acid solution to obtain a mixture of pectin and synephrine, and separating and purifying to obtain pectin and synephrine products. Extracting with sodium carbonate solution to obtain fructus Aurantii Immaturus total flavone product. Extracting with sodium hydroxide to obtain hesperidin product. Finally, the extracted slag is relatively pure plant fiber. The invention utilizes a plurality of methods to comprehensively develop various products from the immature bitter orange, and ensures the complete utilization of materials, thereby reducing the production cost and reducing the environmental pollution.
BACKGROUND AND OBJECTIVE: Time series data plays a crucial role in the realm of the Internet of Things Medical (IoMT). Through machine learning (ML) algorithms, online time series classification in IoMT systems enables reliable real-time disease detection. Deploying ML algorithms on edge health devices can reduce latency and safeguard patients' privacy. However, the limited computational resources of these devices underscore the need for more energy-efficient algorithms. Furthermore, online time series classification inevitably faces the challenges of concept drift (CD) and catastrophic forgetting (CF). To address these challenges, this study proposes an energy-efficient Online Time series classification algorithm that can solve CF and CD for health devices, called OTCD.
METHODS: OTCD first detects the appearance of concept drift and performs prototype updates to mitigate its impact. Afterward, it standardizes the potential space distribution and selectively preserves key training parameters to address CF. This approach reduces the required memory and enhances energy efficiency. To evaluate the performance of the proposed model in real-time health monitoring tasks, we utilize electrocardiogram (ECG) and photoplethysmogram (PPG) data. By adopting various feature extractors, three arrhythmia classification models are compared. To assess the energy efficiency of OTCD, we conduct runtime tests on each dataset. Additionally, the OTCD is compared with state-of-the-art (SOTA) dynamic time series classification models for performance evaluation.
RESULTS: The OTCD algorithm outperforms existing SOTA time series classification algorithms in IoMT. In particular, OTCD is on average 2.77% to 14.74% more accurate than other models on the MIT-BIH arrhythmia dataset. Additionally, it consumes low memory (1 KB) and performs computations at a rate of 0.004 GFLOPs per second, leading to energy savings and high time efficiency.
CONCLUSION: Our proposed algorithm, OTCD, enables efficient real-time classification of medical time series on edge health devices. Experimental results demonstrate its significant competitiveness, offering promising prospects for safe and reliable healthcare.
The invention has the following patents: can cure aplastic anemia, and the price of the traditional Chinese medicine can be accepted by families of common patients. The invention has the following patents: the hereditary secret formula is invented by using the study of students, comprehension and medical experience in a lifetime after being handed down from ancestors, and the hereditary secret formula is left. The invention has the technical characteristics that: 30g of hairyvein agrimony, 30g of donkey-hide gelatin, 20g of cuttle bone, 30g of beautyberry and 5g of bletilla striata. Is prepared from five Chinese-medicinal materials. The invention has the following patents: can restore and enhance the hematopoietic function of human body. The application method of the invention comprises the following steps: decocting with water or making into powder, and making into honeyed pill; or making into powder, capsule, and honeyed pill.
This is an observational retrospective study where data will be collected from a medical claims database derived from a large national managed care organization with over five million members. Members enrolled in a Medicare supplement program will also be included. The objective of this study is to determine the incidence of cancer among patients who have used REGRANEX (becaplermin) compared to patients who have not used REGRANEX (becaplermin). REGRANEX (becaplermin) is an FDA-approved prescription medicine that contains a platelet-derived growth factor that is used for the treatment of foot ulcers in patients with diabetes. Patients who were treated with REGRANEX (becaplermin) between January 1998 and June 2003 will be identified in a health insurance claims database. Another group of patients who have not been treated with REGRANEX (becaplermin) but have similar characteristics to patients treated with REGRANEX (becaplermin) will also be identified during the same time frame in the database. Medical record abstraction and review will be conducted to verify all incident cancers identified. Follow-up for study outcomes will be conducted from the date of accrual through termination of health-plan membership or December 2003 (whichever comes first). The date of accrual is the date of REGRANEX (becaplermin) exposure for each exposed patient and his or her matched unexposed comparison patients. Any incidence of death from cancer will also be identified. The primary outcome measure in the study will be the incidence rate of cancers of all kinds, grouped by organ site in patients who have used REGRANEX (becaplermin) and patients who have not used REGRANEX (becaplermin). A secondary objective is a similar comparison of the incidence of death from cancer. This is an observational study; no investigational drug will be administered.
BACKGROUND: GAPO syndrome is a rare autosomal recessive disorder characterized by the acronym of growth retardation, alopecia, pseudo-anodontia and progressive optic atrophy. While the genetic alteration of the ANTXR1 gene has been known for its cause, the full range of its clinical and genetic manifestations is not well explored due to the syndrome's extreme rarity.
MATERIALS/METHODS: We report two children born to a non-consanguineous parent in India with classical features of GAPO syndrome. The whole exome sequencing analysis (WES) was performed in both siblings, and the parent's genetic and clinical status was determined. The identified variation was characterized in silico using homology-based protein modelling.
RESULTS: In WES analysis, a homozygous ANTXR1 gene indel variant c. 151_152 + 2delAAGT (p.Lys51fs) was identified in both siblings. The parents were identified as the carriers of the ANTXR1 variant. Additionally, they also displayed mild GAPO-related facial and glaucomatous features. In silico analysis and homology-based ANTXR1 protein structure illustrate a frameshift and the subsequent premature truncation of the protein.
CONCLUSIONS: Our reports contribute to the comprehension of GAPO syndrome within the Indian context describing an ANTXR1 novel variant causing premature protein truncation. WES-based genetic testing can significantly aid in expertly diagnosing GAPO syndrome. In the present case scenario, a variable penetrance of ANTXR1 variation was acknowledged as the carrier parents also had a mild degree of GAPO-related features. Future reports that include parental clinical diagnosis can offer further insights in this context.
PROBLEM TO BE SOLVED: To obtain the subject new inhibitor containing eugeniin, an ingredient extracted from natural plants, Geumjaponicum Thunb. and Syzygium aromaticum (L.) Merr., as an active ingredient, not having toxicity, and capable of inhibiting only the synthesis of virus DNA without affecting substrates. SOLUTION: This inhibitor contains eugeniin of formula I (G is a group of formula II) as an active ingredient. The eugeniin is obtained e.g. by extracting Geumjaponicum Thunb. with hot water, extracting the extract with ethyl acetate, removing the ethyl acetate, extracting the residue with methanol, fractionating the methanol-soluble fraction with column chromatography, and subsequently treating the obtained active fraction with reverse phase high performance liquid chromatography.
Subjects will receive CT 327 on 2 of 4 target lesions located on one side of their body. On the remaining 2 target lesions on the other side of their body, placebo will be applied.
INTRODUCTION: Patients with cirrhosis awaiting liver transplantation (LT) are often frail, and malnourished. The period of time on the waitlist provides an opportunity to improve their physical fitness. Prehabilitation appears to improve the physical fitness of patients before major surgery. Little is known about prehabilitation in patients with cirrhosis. The aim of this feasibility study will be to investigate the feasibility, safety, and effectiveness of a multimodal prehabilitation programme in this patient population.
METHODS AND ANALYSIS: This is an open-label single-arm feasibility trial recruiting 25 consecutive adult patients with cirrhosis active on the LT waiting list of the McGill University Health Centre (MUHC). Individuals will be excluded based on criteria developed for the safe exercise training in patients with cirrhosis. Enrolled individuals will participate in a multimodal prehabilitation programme conducted at the PeriOperative Programme complex of the MUHC. It includes exercise training with a certified kinesiologist (aerobic and resistance training), nutritional optimisation with a registered dietician and psychological support with a nurse specialist. The exercise training programme is divided into an induction phase with three sessions per week for 4 weeks followed by a maintenance phase with one session every other week for 20 weeks. Aerobic training will be individualised based on result from cardiopulmonary exercise testing (CPET) and will include a high-intensity interval training on a cycle ergometer. Feasibility, adherence and acceptability of the intervention will be assessed. Adverse events will be reviewed before each visit. Changes in exercise capacity (6-minute walk test, CPET, liver frailty index), nutritional status and health-related quality of life will be assessed during the study. Post-transplantation outcomes will be recorded.
ETHICS AND DISSEMINATION: The research ethics board of the MUHC has approved this study (2021-7646). Our findings will be submitted for presentation at national and international conferences, and for peer-reviewed publication.
TRIAL REGISTRATION NUMBER: NCT05237583.
PURPOSE: A detergent cosmetic composition is provided, for cleansing, caring, conditioning and/or styling keratin materials such as hair. CONSTITUTION: A detergent cosmetic composition comprises cosmetically acceptable media; 4-50 wt% of detergent base; 0.01-10 wt% of at least one cationic polymer; and 0.05-10 wt% of at least one water-soluble anionic polycondensate containing at least one polyurethane and/or polyurea block. The detergent base is anionic surfactants, amphiphilic surfactants, nonionic surfactants or their mixture. The polycondensate is prepared by block arrangement of (1) at least one compound containing two or more active hydrogen atoms per molecule; (2) at least one diol, or diol mixture containing acid radical or its salt; and (3) at least one di- or polyisocyanate. Preferably the compound (1) is selected from the group consisting of diols, diamines, polyesterols, polyetherols and their mixture, and the compound (2) is 2,2-hydroxymethylcarboxylic acid. More preferably the cationic polymer is selected from quaternary cellulose ether derivatives, cyclopolymer, cationic polysaccharide, vinyl pyrrolidone/methacrylamidopropyldimethylamine copolymer and their mixture. The pH of the composition is preferably 4-9.
FIELD: medicine, pharmacy, peptides. SUBSTANCE: invention relates to the production of drugs used in medicinal practice and preparing preparations from animal raw, namely biologically active peptides showing an antigonadotropic activity. Method involves the use of epiphysis glands (epiphysis) KPC which are milled, extracted with acetic acid solution, frozen at -5-20 C and thawed. Then the preliminary cleared extract is subjected for ultrafiltration in tangential flow on membranes at the threshold passing through 10 kDa. EFFECT: increased yield of the end product per the raw unit, good technology and ecology of production. 1 dwg, 1 tbl, 2 ex
Small fiber neuropathy (SFN) is a peripheral nerve condition affecting thin myelinated Aδ and unmyelinated C-fibers, characterized by severe neuropathic pain and other sensory and autonomic symptoms. A variety of medical disorders can cause SFN; however, more than 50% of cases are idiopathic (iSFN). Some investigations suggest an autoimmune etiology, backed by evidence of the efficacy of IVIG and plasma exchange. Several studies suggest that autoantibodies directed against nervous system antigens may play a role in the development of neuropathic pain. For instance, patients with CASPR2 and LGI1 antibodies often complain of pain, and in vitro and in vivo studies support their pathogenicity. Other antibodies have been associated with SFN, including those against TS-HDS, FGFR3, and Plexin-D1, and new potential targets have been proposed. Finally, a few studies reported the onset of SFN after COVID-19 infection and vaccination, investigating the presence of potential antibody targets. Despite these overall findings, the pathogenic role has been demonstrated only for some autoantibodies, and the association with specific clinical phenotypes or response to immunotherapy remains to be clarified. The purpose of this review is to summarise known autoantibody targets involved in neuropathic pain, putative attractive autoantibody targets in iSFN patients, their potential as biomarkers of response to immunotherapy and their role in the development of iSFN.
A research coordinator from Weill Cornell Medical College will survey the medical records of all 31 subjects, and obtain contact information for all living subjects. Living subjects will be called by the research coordinator at Stony Brook University Medical Center and invited to participate in the current follow-up study, which will entail a full medical chart review. If the potential subject is interested, he/she will be invited to Stony Brook University Medical Center where Dr. Rosengart or a designated co-investigator conducts the informed consent process. However, subjects who are unable to travel to Stony Brook University Medical Center will be mailed the consent form. Those who consent to participate will compile their medical records and send them to Stony Brook University Medical Center. The research coordinator at Stony Brook will conduct a chart review in order to collect information regarding the subject's medication, evaluation and surgical history over the past 10 years. This information will include cardiac health evaluations such as 99mTc-sestamibi SPECT, treadmill exercise tolerance test and cardiac specific blood tests. These parameters will be compared to evaluations done at baseline and evaluations done at the subject's last visit as a participant of either Institutional Review Board (IRB) protocol #0794-894 or #0297-693.